American Association for the Study of Liver Diseases and Korean Association for the Study of the Liver Community Conversation: Redefining Risk in Chronic Liver Disease

This community conversation between the American Association for the Study of Liver Diseases and the Korean Association for the Study of the Liver addresses a fundamental question in hepatology: How do we better identify which patients with chronic liver disease are at highest risk? Leading experts from both organizations discuss 3 areas where the approach to risk assessment is changing. First, presenters examine how new data on chronic hepatitis B are shifting treatment thresholds and strategies for preventing hepatocellular carcinoma. Next, speakers explore how real-world evidence, emerging biomarkers, and noninvasive tools are being incorporated into clinical practice—and where gaps remain. Finally, presenters explore which artifical intelligence–based prediction tools are ready for clinical use and discuss practical approaches for implementing them. This program offers an opportunity to hear different perspectives on these issues from experts representing 2 major liver societies, and consider how these advances can be translated into better patient care.